 |
 |
 |
 |
February 3, 2006
| Termination of Joint Development with Seikagaku Corporation |
 |
 |
|
Seikagaku Corporation and AnGes MG, Inc. have been collaborating in the
development of an intra-articular injection formulation using NFκB decoy
oligodeoxynucleotide (NFκB decoy oligo). AnGes MG has announced that both
companies have agreed to terminate such joint development activities.
The purpose of this joint development was, to optimize an effective intra-articular
injection formulation, using NFκB decoy oligo for treating rheumatoid arthritis and
osteoarthritis.
Seikagaku Corporation decided to terminate its participation to the joint development
activities because of economical reasons associated with the prolonged development
period. AnGes MG will continue development of a novel intra-articular injectable
formulation with NFκB decoy oligo for rheumatoid arthritis and osteoarthritis. |
|
|
